Arun Rajan

Dr. Arun Rajan


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
DHDanh-Tai Hoang
Danh-Tai Hoang
GDGal Dinstag
Gal Dinstag
ESEldad D. Shulman
Eldad D. Shulman
LHLeandro C. Hermida
Leandro C. Hermida
DBDoreen S. Ben-Zvi
Doreen S. Ben-Zvi
EREytan Ruppin
Eytan Ruppin

21 October 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SBSylvan C. Baca
Sylvan C. Baca
JSJi-Heui Seo
Ji-Heui Seo
MDMatthew P. Davidsohn
Matthew P. Davidsohn
BFBrad Fortunato
Brad Fortunato
KSKarl Semaan
Karl Semaan
MFMatthew Freedman
Matthew Freedman
Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the transcriptional programs that govern cancer phenotypes and their dynamic changes during the course of disease. To address these limitations, we developed a method for comprehensive epigenomic profiling of cancer from 1 ml of patient plasma. Using an immunoprecipitation-based approach targeting histone modifications and DNA methylation, we measured 1,268 epigenomic profiles in plasma from 433 individuals with one of 15 cancers. Our assay provided a robust proxy for transcriptional activity, allowing us to infer the expression levels of diagnostic markers and drug targets, measure the activity of therapeutically targetable transcription factors and detect epigenetic mechanisms of resistance. This proof-of-concept study in advanced cancers shows how plasma epigenomic profiling has the potential to unlock clinically actionable information that is currently accessible only via direct tissue sampling.

21 October 2019 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ARArun Rajan
Arun Rajan
CHChristopher R. Heery
Christopher R. Heery
ATAnish Thomas
Anish Thomas
AMAndrew Mammen
Andrew Mammen
SPSusan Perry
Susan Perry
JGJames L. Gulley
James L. Gulley
Background Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmunity. PD-1–targeting antibodies have been evaluated, largely in patients with thymic carcinoma. We sought to evaluate the efficacy and safety of the anti-PD-L1 antibody, avelumab (MSB0010718C), in patients with relapsed, advanced thymic epithelial tumors and conduct correlative immunological studies. Methods Seven patients with thymoma and one patient with thymic carcinoma were enrolled in a phase I, dose-escalation trial of avelumab (MSB0010718C), and treated with avelumab at doses of 10 mg/kg to 20 mg/kg every 2 weeks until disease progression or development of intolerable side effects. Tissue and blood immunological analyses were conducted. Results Two of seven (29%) patients with thymoma had a confirmed Response Evaluation Criteria in Solid Tumors–defined partial response, two (29%) had an unconfirmed partial response and three patients (two thymoma; one thymic carcinoma) had stable disease (43%). Three of four responses were observed after a single dose of avelumab. All responders developed immune-related adverse events that resolved with immunosuppressive therapy. Only one of four patients without a clinical response developed immune-related adverse events. Responders had a higher absolute lymphocyte count, lower frequencies of B cells, regulatory T cells, conventional dendritic cells, and natural killer cells prior to therapy. Conclusion These results demonstrate anti-tumor activity of PD-L1 inhibition in patients with relapsed thymoma accompanied by a high frequency of immune-related adverse events. Pre-treatment immune cell subset populations differ between responders and non-responders. Trial registration ClinicalTrials.gov - NCT01772004. Date of registration – January 21, 2013.

19 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
DLDelphine Lissa
Delphine Lissa
NTNobuyuki Takahashi
Nobuyuki Takahashi
PDParth Desai
Parth Desai
IMIrena Manukyan
Irena Manukyan
CSChristopher W. Schultz
Christopher W. Schultz
ATAnish Thomas
Anish Thomas
Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key transcription regulators have recently been proposed in cell lines and limited number of primary tumors. The clinical and biological implications of neuroendocrine (NE) subtypes in metastatic SCLC, and the extent to which they vary within and between patient tumors and in patient-derived models is not known. We integrate histology, transcriptome, exome, and treatment outcomes of SCLC from a range of metastatic sites, revealing complex intra- and intertumoral heterogeneity of NE differentiation. Transcriptomic analysis confirms previously described subtypes based on ASCL1, NEUROD1, POU2F3, YAP1, and ATOH1 expression, and reveal a clinical subtype with hybrid NE and non-NE phenotypes, marked by chemotherapy-resistance and exceedingly poor outcomes. NE tumors are more likely to have RB1, NOTCH, and chromatin modifier gene mutations, upregulation of DNA damage response genes, and are more likely to respond to replication stress targeted therapies. In contrast, patients preferentially benefited from immunotherapy if their tumors were non-NE. Transcriptional phenotypes strongly skew towards the NE state in patient-derived model systems, an observation that was confirmed in paired patient-matched tumors and xenografts. We provide a framework that unifies transcriptomic and genomic dimensions of metastatic SCLC. The marked differences in transcriptional diversity between patient tumors and model systems are likely to have implications in development of novel therapeutic agents.

6 July 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
AWAbigail Wong-Rolle
Abigail Wong-Rolle
QDQiang Dong
Qiang Dong
YZYunhua Zhu
Yunhua Zhu
PDPrajan Divakar
Prajan Divakar
JHJyh Liang Hor
Jyh Liang Hor
CZChen Zhao
Chen Zhao
Background The lung intratumor microbiome influences lung cancer tumorigenesis and treatment responses, but detailed data on the extent, location, and effects of microbes within lung tumors are missing, information needed for improved prognosis and treatment. Methods To address this gap, we developed a novel spatial meta-transcriptomic method simultaneously detecting the expression level of 1,811 host genes and 3 microbe targets (bacteria, fungi, and cytomegalovirus). After rigorous validation, we analyzed the spatial meta-transcriptomic profiles of tumor cells, T cells, macrophages, other immune cells, and stroma in surgically resected tumor samples from 12 patients with early-stage lung cancer. Results Bacterial burden was significantly higher in tumor cells compared with T cells, macrophages, other immune cells, and stroma. This burden increased from tumor-adjacent normal lung and tertiary lymphoid structures to tumor cells to the airways, suggesting that lung intratumor bacteria derive from the latter route of entry. Expression of oncogenic β-catenin was strongly correlated with bacterial burden, as were tumor histological subtypes and environmental factors. Conclusions Intratumor bacteria were enriched with tumor cells and associated with multiple oncogenic pathways, supporting a rationale for reducing the local intratumor microbiome in lung cancer for patient benefit. Trial registration number NCT00242723, NCT02146170.

1 February 2017 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
CKChul Kim
Chul Kim
CHChuong D. Hoang
Chuong D. Hoang
AKAparna Kesarwala
Aparna Kesarwala
DSDavid S. Schrump
David S. Schrump
UGUdayan Guha
Udayan Guha
ARArun Rajan
Arun Rajan